An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer
-
Published:2020-02
Issue:2
Volume:38
Page:40.e17-40.e24
-
ISSN:1078-1439
-
Container-title:Urologic Oncology: Seminars and Original Investigations
-
language:en
-
Short-container-title:Urologic Oncology: Seminars and Original Investigations
Author:
Daniels Marcus J.,
Barry Emily,
Milbar NivORCID,
Schoenberg Mark,
Bivalacqua Trinity J.,
Sankin Alex,
Kates Max
Reference35 articles.
1. Cancer statistics, 2019;Siegel;Ca Cancer J Clin,2019
2. Epidemiology and risk factors of urothelial bladder cancer;Burger;Eur Urol,2013
3. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000;David;Cancer,2009
4. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016;Burger;Eur Urol,2017
5. Guideline for the management of non- muscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update;Hall;J Urol,2007
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献